Skip to main content

Faeth Therapeutics, Inc.

FTH
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001829802

No open-market purchases or sales by Faeth Therapeutics, Inc. insiders were filed in the last 90 days; 45 institutions reported holding it in 13F filings for Q2 2026, worth $333.8M in total; no superinvestor holds it.

Q3 2024 vs. Q2 2024

How the institutions holding Faeth Therapeutics, Inc. changed between Q2 2024 and Q3 2024.

All holders in Q3 2024All holders in Q2 2024

13F holders of FTH: Q2 2024 compared with Q3 2024
MeasureQ2 2024Of which not filed for Q3 2024Q3 2024Change
Holders24119−4
Shares2.11M7.78K2.21M+106.8K (+5.1%)
Value$1.31M$4.82K$1.32M+$18.3K (+1.4%)

1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (1)

Institutions that held Faeth Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.

Institutions new to FTH in Q3 2024
InstitutionSharesValue% of portfolio
Susquehanna International Group, LLP90,428$54.1K0.00%

Sold out (5)

Institutions that held Faeth Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.

Institutions that sold out of FTH in Q3 2024
InstitutionShares, Q2 2024Value, Q2 2024
Two Sigma Securities, LLC18,600$11.5K
Leo Wealth, LLC14,845$9.21K
Banque Cantonale Vaudoise3,900$2.00K
Qube Research & Technologies Ltd4$2
Royal Bank of Canada247$0

Not filed for Q3 2024 yet (1)

Institutions that held Faeth Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding FTH in Q2 2024 that haven't filed for Q3 2024
InstitutionShares, Q2 2024Value, Q2 2024
BlackRock Inc.7,777$4.82K